Objectives: To determine the activity of oritavancin against methicillin-resistant staphylococci, vancomycinresistant enterococci (VRE) and b-haemolytic streptococci recently isolated from acute bacterial skin and skin structure infections or bacteraemia in western Europe.
Introduction
Oritavancin is a semi-synthetic lipoglycopeptide currently in global Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). This novel compound has demonstrated clinical effectiveness in two previous Phase 3 trials. 1 Oritavancin is a promising new agent in the treatment of Gram-positive infections, including those caused by multidrug-resistant Staphylococcus aureus 2 and enterococci. 3 This current study evaluated the in vitro activity of oritavancin and comparators against recently circulating methicillinresistant staphylococci, vancomycin-resistant enterococci (VRE) and b-haemolytic streptococci from western Europe.
Materials and methods
A total of approximately 1000 isolates were sought from a target network of 41 collecting centres in France (8), Germany (8), Italy (9), Spain (8) and the UK (8) between 1 January 2011 and 30 June 2011. The target isolates (n¼25) to be collected per centre were five each of methicillin-resistant S. aureus (MRSA), methicillin-resistant coagulasenegative staphylococci (MRCoNS), Streptococcus pyogenes, Streptococcus agalactiae and VRE. Isolates were re-identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) or Lancefield grouping as required. Methicillin resistance in staphylococci was confirmed by cefoxitin disc screen as described by the CLSI. trimethoprim/sulfamethoxazole were determined by broth microdilution methodology using dried panels supplied by TREK Diagnostics (East Grinstead, UK). The plates have been validated as equivalent to the approved CLSI testing method for oritavancin, which includes 0.002% polysorbate-80. 5 Zone diameters were determined for erythromycin, chloramphenicol, kanamycin, tobramycin and gentamicin following CLSI procedures. 4 Susceptibility to comparators was determined using breakpoints set by the CLSI. 6 No CLSI or EUCAST breakpoints are currently available for oritavancin.
Results

Isolate collection
A total of 866 Gram-positive isolates were collected, representing 86.6% of the target of 1000 isolates ( Table 1 ). The shortfall was mainly due to difficulty in collecting eligible VRE isolates from France, Italy, Spain and the UK [n¼ 15 (37.5%), n¼ 26 (57.8%), n¼ 6 (15.0%) and n¼ 16 (40.0%), respectively]. The majority of the VRE isolates collected were vancomycin-resistant Enterococcus faecium and only 17 vancomycin-resistant Enterococcus faecalis isolates were collected (Table 1) . A total of 492 isolates (57%) were from ABSSSIs and the remainder (374 isolates, 43%) were from bacteraemia (data not shown).
Summary of oritavancin activity
Cumulative distributions of the MICs of oritavancin for MRSA, MRCoNS, S. pyogenes, S. agalactiae and VRE are shown in Figure 1 . Overall, the MIC 50 and MIC 90 of oritavancin were, respectively, 0.03 and 0.06 mg/L for MRSA, 0.06 and 0.12 mg/L for MRCoNS, 0.03 and 0.06 mg/L for VRE (predominantly E. faecium), 0.06 and 0.25 mg/L for S. pyogenes and 0.03 and 0.06 mg/L for S. agalactiae. Only a small number of vancomycinresistant E. faecalis isolates were collected (n¼ 17), but these resulted in a slightly higher oritavancin MIC distribution (MIC 90 0.25 mg/L) than vancomycin-resistant E. faecium isolates. Summary MIC and susceptibility data are shown in Table S1 (available as Supplementary data at JAC Online).
Activity against MRSA
Oritavancin inhibited all strains of MRSA at ≤0.25 mg/L (Figure 1) , and all MRSA strains were fully susceptible to linezolid, vancomycin and teicoplanin. Against one isolate from Germany, the MIC of tigecycline was 0.5 mg/L (overall tigecycline susceptibility 99.5%), and against three isolates from Italy the MIC of daptomycin was 2 or 4 mg/L (overall daptomycin susceptibility 98.5%). MIC data for MRSA are shown in Table S1 .
Activity against MRCoNS
Oritavancin inhibited all strains of MRCoNS at ≤0.25 mg/L (Figure 1 ). An analysis of MIC data for MRCoNS is given in Table S1 . Six isolates of Staphylococcus epidermidis (one from Italy and five from Germany) were resistant to tigecycline (MIC.1 mg/L). Four isolates (one Staphylococcus capitis from Germany, two S. epidermidis from Germany and one Staphylococcus pettenkoferi from Italy) were daptomycin-non-susceptible (all MICs of 2 mg/L). Three S. epidermidis isolates (one from Spain and two from Italy) were resistant to linezolid (MIC .8 mg/L). Interestingly, the isolate from Spain showed a Cfr phenotype with co-resistance to clindamycin and chloramphenicol, but not erythromycin. Activity of oritavancin against Gram-positive bacteria 165 
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Activity against b-haemolytic streptococci
Oritavancin inhibited all strains of b-haemolytic streptococci at ≤0.25 mg/L (Figure 1 ). Resistance to antimicrobials by S. pyogenes was generally infrequent (≤1%); however, higher rates of resistance were seen to tetracycline (11.5%), erythromycin (7.3%) and chloramphenicol (2.1%) (Table S1 ). Resistance to most antimicrobials by S. agalactiae was also rare (≤0.5%); however, very high resistance was observed to tetracycline, at 81.9% for all countries combined, and some resistance was also found to erythromycin (22.8%), clindamycin (18.1%) and chloramphenicol (1.6%) (Table S1 ).
Activity against VRE
Oritavancin inhibited all strains of VRE at ≤0.25 mg/L (Figure 1 ). Twenty-two VRE strains retained susceptibility to teicoplanin (21.8%), suggesting that these isolates had a vanB genotype. Three linezolid-resistant E. faecium isolates were found in two sites in Germany (MIC.8 mg/L). Two isolates from France (one E. faecium and one Enterococcus hirae) were non-susceptible to daptomycin (MIC.4 mg/L). Three isolates of VRE [one from Germany (E. faecalis) and two from Italy (one E. faecalis and one E. faecium)] were non-susceptible to tigecycline (MIC 0.5 mg/L). More than 90% of VRE isolates were resistant to erythromycin or levofloxacin and more than 70% were resistant to cotrimoxazole or ampicillin. Overall, around 40%-50% of isolates were resistant to tetracycline or high-level gentamicin. Only chloramphenicol showed low-level resistance (5.9% overall) (Table S1 ).
Discussion
In summary, oritavancin showed potent activity against currently circulating methicillin-resistant staphylococci, VRE and b-haemolytic streptococci in western Europe. As a whole, Grampositive isolates from France, Germany, Italy, Spain and the UK showed variable resistance to other antimicrobial agents that had no effect on the activity of oritavancin. These included MRCoNS and VRE isolates with high levels of resistance to most other antimicrobial agents and also isolates with decreased susceptibility to linezolid and daptomycin. The MIC of oritavancin was not greater than 0.25 mg/L for any strains of any organism group tested in this study. These data are virtually identical to those found in a previous study of European Gram-positive isolates collected between 2005 and 2008. 7 The exception was the activity of oritavancin against S. agalactiae; we found an MIC 90 of 0.06 mg/L compared with a slightly higher MIC of 0.25 mg/L reported previously. 7 Our findings also complement the data of Mendes et al., 3 who reported strong activity of oritavancin against US and European isolates of vanA-positive E. faecium and vanA-positive E. faecalis, albeit with a slightly higher MIC distribution for the latter.
There was evidence among the isolates collected from Europe of non-susceptibility and resistance to other agents, such as linezolid, daptomycin and tigecycline, albeit at relatively low rates. As a reduction in susceptibility to these newer agents is inevitable sooner or later, the introduction of oritavancin as a treatment option for Gram-positive bacterial infections would increase the number of drugs that are active against these pathogens.
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